OneDigital Investment Advisors LLC Has $1.56 Million Stock Position in Cencora, Inc. (NYSE:COR)

OneDigital Investment Advisors LLC reduced its holdings in Cencora, Inc. (NYSE:COR) by 2.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 6,914 shares of the company’s stock after selling 156 shares during the period. OneDigital Investment Advisors LLC’s holdings in Cencora were worth $1,556,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. New Millennium Group LLC acquired a new position in Cencora during the 2nd quarter valued at $26,000. TFO Wealth Partners LLC acquired a new position in shares of Cencora during the first quarter valued at about $30,000. LRI Investments LLC bought a new stake in shares of Cencora in the first quarter valued at about $31,000. MFA Wealth Advisors LLC acquired a new stake in Cencora during the second quarter worth about $30,000. Finally, Concord Wealth Partners bought a new position in Cencora during the third quarter valued at about $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.80% of the company’s stock.

Cencora Trading Down 1.3 %

Shares of COR opened at $240.24 on Monday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The company has a market cap of $47.34 billion, a price-to-earnings ratio of 31.99, a PEG ratio of 1.60 and a beta of 0.44. The stock has a fifty day moving average price of $232.62 and a two-hundred day moving average price of $231.03. Cencora, Inc. has a 52-week low of $194.23 and a 52-week high of $251.56.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.92%. Cencora’s dividend payout ratio is 27.16%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on COR shares. Leerink Partners decreased their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Barclays lifted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company increased their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.